COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core

COBRE 抗菌素耐药性和治疗发现中心 - 行政核心

• 批准号: 10488622
• 负责人: ERIKA M D'AGATA
• 金额: $ 45.71万
• 依托单位: MIRIAM HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-18 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10488622
• 关键词: Advisory Committees; Antimicrobial Resistance; Award; Biological Sciences; Centers of Research Excellence; Communication; Conflict (Psychology); Core Facility; Ensure; Environment; Faculty; Fostering; Funding; Goals; Grant; Hospitals; Individual; Infrastructure; Institution; Laboratories; Mentors; Mission; Monitor; National Institute of General Medical Sciences; Outcome; Peer Review; Performance; Phase; Philosophy; Process; Publications; Research; Research Personnel; Resistance development; Rhode Island; Science; Services; Therapeutic; United States National Institutes of Health; Universities; Work; base; design; drug development; faculty mentor; organizational structure; outreach; professor; programs; senior faculty

The Miriam Hospital enthusiastically recommends Erika D’Agata, MD, MPH of to be appointed as The Center for Antimicrobial Resistance and Therapeutic Discover (CARTD) Program Director/Principal Investigator (PD/PI) effective March 1, 2023. Administrative Core Summary/Abstract The Administrative Core will provide financial, scientific and technologic stewardship of the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital. Core Director Mylonakis, with the assistance of Deputy Director Nau, will establish overall programmatic goals. These goals and progress toward accomplishing them will be monitored by the Steering Committee, External Advisory Committee, Senior Faculty Mentoring and Advisory Committee (SFMAC) and Program Staff at NIGMS. Our Center’s overall mission is to foster an environment that inspires individuals to pursue rigorous laboratory science by providing technical and mentoring support through our core facilities. We will pursue the following specific aims: (1): The Core will maintain an organizational structure that ensures effective communication between the supervisory, scientific, administrative and service oriented components of the COBRE. (2): The Core will devise strategies to increase the use of CARDT Cores to allow self-sustainability by the end of Phase III. (3): The Core will provide a rigorous mentoring infrastructure to all CARDT principal/pilot investigators. (4): The Core will manage a Pilot Grants Program designed to support the most meritorious research on antimicrobial resistance and drug development.

Miriam医院热情推荐Erika D 'Agata，医学博士，公共卫生硕士被任命为抗菌素耐药性和治疗发现中心（CARTD）项目主任/首席研究员（PD/PI），自2023年3月1日起生效。